This is a repository copy of *Activation of IL-36 molecules and their role in psoriatic disease*.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/111102/

Version: Accepted Version

**Proceedings Paper:**

https://doi.org/10.1111/bjd.14911

© 2016 The Authors BJD © 2016 British Association of Dermatologists. This is the peer reviewed version of the following article: Wittmann, M, Macleod, T, Ainscough, JS et al. (2016) Activation of IL-36 molecules and their role in psoriatic disease. In: British Journal of Dermatology. 20th Anniversary Conference of the British Skin Foundation, Skin Deep - 20 Years of Research, 13 Oct 2016, London, UK. Wiley, p. 68, which has been published in final form at https://doi.org/10.1111/bjd.14911. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. Uploaded in accordance with the publisher's self-archiving policy.

**Reuse**
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Activation of IL-36 molecules and their role in psoriatic disease


University of Leeds, Faculty of Medicine and Health, LIRMM & Faculty of Biological Sciences, SMCB, Leeds, U.K.

The interleukin (IL)-1 family of cytokines are fundamental regulators of the innate immune system, serving to orchestrate inflammation. The recently described IL-1 cytokines IL-36α, IL-36β and IL-36γ have been associated with psoriatic inflammation as well as antifungal defence. IL-36 is highly upregulated in and also a biomarker for skin psoriasis. Loss of function mutation of the endogenous IL-36 antagonist IL-36RA have been reported to be associated with severe pustular psoriasis phenotypes. As with other IL-1 family members, IL-36 cytokines, including the IL-36RA, are expressed as inactive precursors and must be truncated by specific proteases to become bioactive. Therefore, our aim was to identify the protease/s responsible for IL-36 activation and explore the potential importance of this activation to psoriasis. We identified neutrophil elastase as the most important protease in cleaving the antagonist into its active form. Neutrophil derived serine proteases were also able to cleave IL-36 agonists, however not into full activity as the cleavage product was not the most active one. However, keratinocyte based activity assays, showed that IL-36γ activating proteases reside within the lysosome and conditioned media of a number of skin-resident cell types, including fibroblasts and keratinocytes. Importantly, using small-molecule inhibitors we were able to identify the IL-36γ-activating protease as cathepsin S and reproduce this processing using recombinant proteins. In a skin equivalent model, IL-36γ s18, the main product of cathepsin S-dependent IL-36γ cleavage, was shown to induce epidermal differentiation changes indicative of psoriatic inflammation. Finally, using samples extracted by tape-stripping, it was demonstrated that both IL-36γ and cathepsin S are strongly upregulated in the skin of psoriasis patients, relative to healthy controls. Together, these data suggest that the biologic activity of the IL-36 system is determined by both neutrophil proteases and skin expressed cathepsin S both of which are highly expressed in psoriatic inflammation.